-Dr. Stasi brings to SalioGen 30 years of
experience in ophthalmology and genetic medicine-
LEXINGTON, Mass., Aug. 19,
2024 /PRNewswire/ -- SalioGen Therapeutics, a
biotechnology company developing next-generation genetic medicines
based on its novel Gene Coding™ technology, today announced
the appointment of Kalliopi "Kali" Stasi, M.D., Ph.D. as Chief
Medical Officer. In this position, Dr. Stasi will be responsible
for bringing the company's development candidate SGT-1001 into the
clinic by mid-2025 as a one-time treatment for Stargardt disease
and continuing to develop the company's Gene Coding technology for
other inherited retinal diseases and cystic fibrosis.
"Dr. Stasi brings to SalioGen three decades of expertise in
ophthalmology and a proven track record of advancing genetic
medicines from early- and late-stage clinical development through
commercialization," said Jason Cole,
CEO of SalioGen Therapeutics. "Her clinical vision and leadership
will enhance our ability to continue pushing the boundaries of
genetic medicine for patients and families, and we're excited to
welcome Dr. Stasi to our team."
"SalioGen's novel Gene Coding technology holds tremendous
potential for overcoming the limitations of other genetic medicine
approaches, significantly expanding the universe of diseases we can
address by integrating full genes with high specificity," said Dr.
Stasi. "I'm very excited to work with the SalioGen team to
accelerate the positive impact this technology can have on
patients."
Most recently, Dr. Stasi served as Senior Vice President of
Clinical Development at Adverum Biotechnologies. In this role, she
planned and executed global clinical development programs for
vision loss. In her previous position, Dr. Stasi led Tenpoint
Therapeutic's cell therapy program for ophthalmic indications as
Senior Vice President of Clinical Development. Before that, Dr.
Stasi worked at Novartis Institutes for Biomedical Research as a
Translational Medical Director, where she led multiple clinical
trials in a pipeline of gene and cell therapies intended to treat
retinal diseases. Earlier in her career, Dr. Stasi served four
years at the University of Pennsylvania
as an Assistant Professor of Ophthalmology.
Dr. Stasi earned her M.D. and Ph.D. in neurodegenerative disease
from the University of Patras, Greece. She completed an ophthalmology
residency at the University of
Rochester, NY, a Cornea and Refractive Surgery Clinical
fellowship at Johns Hopkins Wilmer Eye Institute, and a business
post-baccalaureate program at Wharton Business School.
About SalioGen Therapeutics
SalioGen Therapeutics is
developing next-generation genetic medicines for patients using its
novel Gene Coding™ technology. Gene Coding is a non-viral
method of integrating large or multiple whole genes into the genome
at precise locations without double-strand breaks or guide RNA.
SalioGen's lead programs focus on one-time treatments for Stargardt
disease and cystic fibrosis. The company is also developing its
Gene Coding technology for additional indications, such as other
inherited retinal diseases, and to engineer CAR-T cells for cancer
and autoimmune conditions. SalioGen is headquartered in
Lexington, Massachusetts. For more
information, visit SalioGen.com and follow SalioGen on
LinkedIn.
Media Contact:
Lori
Rosen
LDR Communications
lori@ldrcommunications.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/saliogen-therapeutics-appoints-kali-stasi-md-phd-as-chief-medical-officer-302224618.html
SOURCE SalioGen Therapeutics